BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-496@pharmaconomics
DTSTAMP:20260707T034519Z
DTSTART;VALUE=DATE:20260329
DTEND;VALUE=DATE:20260330
SUMMARY:BMY Phase 2 — Camzyos
DESCRIPTION:Phase 2 trial results for Camzyos in Hypertrophic Cardiomyopathy are due Mar 29\, 2026. A clean hit validates the program\; a miss can gap the stock down hard.\n\nPrimary source: https://www.sec.gov/Archives/edgar/data/14272/000001427226000008/a2026q1ex991.htm\n\nTrack it: https://www.pharmaconomics.com/e/496
URL:https://www.pharmaconomics.com/e/496
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:BMY catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR